Catalyst Pharmaceuticals

Catalyst makes medicines for rare muscle diseases. These treatments help patients manage difficult health conditions. The company sells three main drugs to patients.

Pills for Rare Diseases

• Firdapse: Tablet used to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare disease affecting nerve-muscle communication; generated $98.9 million in revenue in Q1 2026.
• Agamree: Oral suspension for patients with Duchenne muscular dystrophy (DMD), a genetic disorder causing muscle weakness; brought in $36.7 million in revenue during Q1 2026.
• Fycompa: Prescription medicine for managing various types of seizures in people with epilepsy; accounted for $13.8 million in revenue in Q1 2026.

Strategic Deals and Buyouts

• Entered a merger agreement in May 2026 to be acquired by Angelini Pharma S.p.A..
• Acquired exclusive North American rights for Agamree from Santhera Pharmaceuticals Holdings in July 2023.
• Purchased the United States rights for epilepsy drug Fycompa from Eisai Co., Ltd. in January 2023.
• Completed a public stock offering in January 2024 that raised $140.7 million for acquisitions.
• Partnered with DyDo Pharma to launch Firdapse in the Japanese market in January 2025.

How Catalyst Operates

Catalyst maintains a focused portfolio by acquiring rights to medications that treat specific, underserved rare diseases. The company uses an exclusive distributor model, with one customer accounting for 90% of product revenue in early 2026.

The Recent Financial Scorecard

• Total revenue rose to $149.4 million in Q1 2026, a 5.6% increase from $141.4 million in Q1 2025.
• Net income reached $63.7 million for the first quarter of 2026, up 12.3% year-over-year.
• Operating income grew to $73.2 million in Q1 2026, a 15.6% increase over the previous year.
• Cash and cash equivalents totaled $755.9 million as of March 31, 2026, up from $709.2 million at the end of 2025.
• Free cash flow was $59.6 million in Q1 2026, down 0.8% from $60 million in Q1 2025.

Bottom Line

Catalyst has transitioned from a development-stage firm to a profitable commercial biopharmaceutical company with multiple approved products. Its strategy of acquiring established assets for rare diseases has driven significant revenue and income growth.